Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Glenmark’s GBR 900 for Treatment of Chronic Pain Entering Human Trials

Published: Thursday, May 15, 2014
Last Updated: Thursday, May 15, 2014
Bookmark and Share
The antibody has successfully completed the Phase I enabling preclinical development programme and a Phase I clinical trial application has been filed with the MHRA, UK.

Glenmark Pharmaceuticals S.A. has announced that GBR 900, a novel monoclonal antibody is entering human trials. GBR 900 targets TrkA, a receptor for nerve growth factor (NGF) involved in chronic pain signaling.

In 2010, Glenmark gained an exclusive worldwide license from Lay Line Genomics S.p.A. (Italy) for anti-TrkA antibodies and their entire intellectual property portfolio in the TrkA field. GBR 900 is the optimized anti-TrkA antibody emerging from this exclusive worldwide license.

Glenmark has now completed the Phase I enabling preclinical development programme for GBR 900 and has filed a Phase I clinical trial application with the MHRA, UK. GBR 900 is the first anti-TrkA monoclonal antibody to enter clinical development.

TrkA is the pain-signalling receptor for NGF. Monoclonal antibodies directed against NGF represent one of the rare clinical breakthroughs in chronic pain treatment and have shown excellent clinical activity in inflammatory and neuropathic pain. Unfortunately, development of the class has been curtailed due to suspected toxicity.

In the GLP toxicity studies no dose limiting toxicities were detected with GBR 900, even at high doses tested. This potentially differentiates GBR 900 from anti-NGF antibodies which are dose limited in clinical studies by preclinical toxicity findings at low doses.

Preclinical head to head comparisons with anti-NGF antibodies in animal models of inflammatory pain demonstrated that GBR 900’s efficacy profile compares favorably with anti-NGF antibodies.

Commenting on the progress with GBR 900, Dr. Michael Buschle, President of Biologics and Chief Scientific Officer, Glenmark Pharmaceuticals Ltd. said: “Since we licensed the TrkA IP from Lay Line Genomics we have been able to differentiate GBR 900 from anti-NGF antibodies. We are very excited about the Phase I clinical study starting and expect that this study will extend the preclinical differentiation into a drug which will be clinically differentiated from anti-NGF antibodies.”

"We are extremely pleased that Glenmark has made significant progress with the anti-TrkA project and are excited about the potential start of the first clinical trial of GBR 900," said Ennio Esposito, Sole Director at Lay Line Genomics S.p.A ., Italy.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!